# Asuragen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/asuragen

- Industry: Biotechnology
- Headquarters: Austin, US
- Website: www.asuragen.com
- Total disclosed funding: $80M
- Latest round: Series C (Mar 20, 2013)
- Investors on record: 4

## About

Asuragen Inc. is a biotechnology firm specializing in molecular diagnostics and genetic testing solutions for complex genetic disorders and oncology-related conditions.Founded in 2005 in Austin, US, Asuragen Inc. focuses on molecular diagnostics and genetics, offering innovative solutions in the healthcare sector. The company has undergone strategic developments, including a partial acquisition by Interpace Diagnostics Group in August 2014, which has influenced its operational focus. Asuragen is led by CEO Matthew McManus, with Matt Winkler being a key founder involved in establishing the company's direction. The firm has raised a total of USD 7.50 mn in funding, mainly through its Series C round, with investments from entities like InvestMichigan! Growth Capital Fund and PTV Healthcare Capital. Asuragen's current company valuation stands at USD 107.46 mn.Asuragen, Inc. specializes in molecular diagnostics, genetics, and oncology testing kits aimed at addressing complex genetic disorders and cancers. Their core product offerings include the AmplideX® brand, which encompasses a range of genetic analysis solutions for carrier screening research, such as the AmplideX® Nanopore Carrier Plus Kit, and diagnostic tests like the QuantideX® qPCR BCR-ABL IS Kit, which monitors chronic myeloid leukemia (CML). These products are designed for use in clinical laboratories and are optimized for established laboratory equipment, enabling the detection of various genetic mutations associated with conditions such as fragile X syndrome, Huntington’s disease, and cystic fibrosis. Asuragen’s customer base includes clinical laboratories, research institutions, and healthcare providers across the EMEA region, particularly focusing on European markets where compliance with local diagnostic regulations is a priority. Their innovative solutions are targeted towards enhancing the accuracy and efficiency of genetic testing in oncology and hereditary diseases.Asuragen generates revenue through direct sales of its molecular diagnostics and testing kits, primarily operating on a B2B model with clinical laboratories and healthcare institutions as primary clients. The company structures its transactions around the provision of testing kits, reagents, and accompanying analysis software, facilitating laboratory testing processes. Their flagship products, like the AmplideX® Nanopore Carrier Plus Kit and the QuantideX® qPCR kits, represent significant offerings within the molecular diagnostics sector, contributing to the company’s revenue streams. Pricing strategies are designed to reflect the advanced technology and comprehensive support services provided, ensuring that clients receive reliable, high-quality diagnostic tools tailored to their specific needs. Asuragen's commitment to innovation and quality positions it strongly within the competitive landscape of genetic testing solutions, catering to a growing demand for precise and timely diagnostics in genetic and oncological applications.Asuragen plans to leverage its recent funding from the Series C round to enhance its product line and expand into new markets. The company is currently developing new testing kits aimed at improving genetic diagnosis, with anticipated launches in the upcoming years. Additionally, Asuragen is targeting expansion into new geographic regions, particularly within the European market, to capitalize on growing demands for genetic testing solutions. The recent funding will be critical in supporting these initiatives, including potential investments in research and development and marketing efforts to establish a stronger presence in these areas.

## Funding rounds

- Series C, Mar 20, 2013, $7.5M — PTV Healthcare Capital, InvestMichigan! Growth Capital Fund
- Series C, Aug 11, 2011, $5M — Growth Capital Partners, PTV Healthcare Capital
- Series B, Nov 13, 2007, $18M — Telegraph Hill Partners, PTV Healthcare Capital, InvestMichigan! Growth Capital Fund
- Series A, Jun 1, 2006, $49M — Telegraph Hill Partners, InvestMichigan! Growth Capital Fund

## Investors

- Telegraph Hill Partners (https://capitalatlas.ai/funds/telegraph-hill-partners) — Series A, Series B
- InvestMichigan! Growth Capital Fund — Series A, Series B, Series C
- PTV Healthcare Capital (https://capitalatlas.ai/funds/ptv-healthcare-capital) — Series B, Series C
- Growth Capital Partners — Series C